Companies Morphogen-IX

Finding a treatment for pulmonary arterial hypertension


Morphogen-IX was developing a novel disease modifying therapeutic for pulmonary arterial hypertension.

The company was acquired by Centessa Pharmaceuticals in January 2021

Cambridge Innovation Capital is a leading Series A investor in the Cambridge ecosystem.

We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.

Discover more


Read More